NASDAQ:CNTX Context Therapeutics (CNTX) Stock Forecast, Price & News $0.88 +0.04 (+4.76%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$0.82▼$0.9450-Day Range$0.48▼$0.8852-Week Range$0.47▼$2.52Volume342,023 shsAverage Volume162,004 shsMarket Capitalization$14.05 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Context Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside354.5% Upside$4.00 Price TargetShort InterestHealthy0.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.47Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector470th out of 1,018 stocksPharmaceutical Preparations Industry216th out of 498 stocks 3.0 Analyst's Opinion Consensus RatingContext Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Context Therapeutics has a forecasted upside of 354.5% from its current price of $0.88.Amount of Analyst CoverageContext Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.68% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 15.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTX. Previous Next 3.0 News and Social Media Coverage News SentimentContext Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Context Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for CNTX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.66% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.88% of the stock of Context Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($1.26) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Context Therapeutics (NASDAQ:CNTX) StockContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Read More Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Stock News HeadlinesMay 20, 2023 | americanbankingnews.comAnalysts Offer Predictions for Context Therapeutics Inc.'s Q2 2023 Earnings (NASDAQ:CNTX)May 17, 2023 | americanbankingnews.comContext Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Increase in Short InterestMay 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>May 16, 2023 | benzinga.comASCO 2023 Spotlight: Claudin 6 Anticipated To ShineMay 16, 2023 | americanbankingnews.comContext Therapeutics Inc. (NASDAQ:CNTX) to Post Q2 2023 Earnings of ($0.23) Per Share, HC Wainwright ForecastsMay 11, 2023 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports First Quarter 2023 Operating and Financial ResultsMay 11, 2023 | markets.businessinsider.comContext Therapeutics (CNTX) Gets a Hold from H.C. WainwrightMay 10, 2023 | finance.yahoo.comContext Therapeutics Reports First Quarter 2023 Operating and Financial ResultsMay 27, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>April 28, 2023 | americanbankingnews.comReviewing Context Therapeutics (CNTX) & The CompetitionApril 24, 2023 | proactiveinvestors.comContext Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual MeetingApril 18, 2023 | finance.yahoo.comSignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A DifferenceApril 18, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)April 14, 2023 | proactiveinvestors.comContext Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinarApril 14, 2023 | benzinga.comSignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A DifferenceApril 3, 2023 | finance.yahoo.comContext Therapeutics to Participate in Two April 2023 Investor ConferencesMarch 29, 2023 | americanbankingnews.comContext Therapeutics Inc. to Post Q1 2023 Earnings of ($0.16) Per Share, HC Wainwright Forecasts (NASDAQ:CNTX)March 25, 2023 | americanbankingnews.comHC Wainwright Downgrades Context Therapeutics (NASDAQ:CNTX) to NeutralMarch 24, 2023 | bizjournals.comContext Therapeutics discontinues development of lead drug candidate, shifts to new targetMarch 24, 2023 | americanbankingnews.comFY2027 Earnings Estimate for Context Therapeutics Inc. (NASDAQ:CNTX) Issued By HC WainwrightMarch 23, 2023 | proactiveinvestors.comContext Therapeutics announces pipeline update with FY 2022 financial resultsMarch 23, 2023 | finanznachrichten.deContext Therapeutics Inc.: Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesMarch 23, 2023 | markets.businessinsider.comH.C. Wainwright downgrades Context Therapeutics (CNTX) to a HoldMarch 22, 2023 | finance.yahoo.comContext Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesMarch 15, 2023 | proactiveinvestors.comContext Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meetingMarch 15, 2023 | finance.yahoo.comContext Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023February 13, 2023 | benzinga.comDiamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Company Calendar Today5/27/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNTX CUSIPN/A CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+354.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,840,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.45% Return on Assets-45.19% Debt Debt-to-Equity RatioN/A Current Ratio9.86 Quick Ratio9.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.49Miscellaneous Outstanding Shares15,970,000Free Float14,903,000Market Cap$14.05 million OptionableNot Optionable Beta2.27 Key ExecutivesMr. Martin A. Lehr (Age 38)Co-Founder, Pres, CEO & Director Comp: $523.71kMs. Jennifer Minai-Azary (Age 44)CFO & Treasurer Comp: $404.33kMr. Alex C. Levit Esq. (Age 43)Chief Legal Officer & Corp. Sec. Comp: $490.82kDr. Felix Kim Ph.D.Co-founder & Chair of Scientific Advisory BoardMr. Christopher Beck M.B.A.Sr. VP of OperationsDr. Tarek Sahmoud M.D. (Age 61)Ph.D., Chief Medical Officer Dr. Evan G. Dick (Age 70)Sr. VP of R&D Ms. Elizabeth Nemchik CPAControllerMore ExecutivesKey CompetitorsCingulateNASDAQ:CINGApplied Molecular TransportNASDAQ:AMTIMarker TherapeuticsNASDAQ:MRKRLipella PharmaceuticalsNASDAQ:LIPODominariNASDAQ:DOMHView All CompetitorsInsiders & InstitutionsTwo Sigma Investments LPBought 29,154 shares on 5/15/2023Ownership: 0.349%Martin A LehrBought 5,823 shares on 2/21/2023Total: $4,891.32 ($0.84/share)Martin A LehrBought 5,606 shares on 2/13/2023Total: $4,877.22 ($0.87/share)Martin A LehrBought 5,040 shares on 2/6/2023Total: $4,888.80 ($0.97/share)Martin A LehrBought 7,027 shares on 1/30/2023Total: $4,918.90 ($0.70/share)View All Insider TransactionsView All Institutional Transactions CNTX Stock - Frequently Asked Questions Should I buy or sell Context Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNTX, but not buy additional shares or sell existing shares. View CNTX analyst ratings or view top-rated stocks. What is Context Therapeutics' stock price forecast for 2023? 1 equities research analysts have issued 1-year price objectives for Context Therapeutics' stock. Their CNTX share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 354.5% from the stock's current price. View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts. How have CNTX shares performed in 2023? Context Therapeutics' stock was trading at $0.6517 at the beginning of the year. Since then, CNTX shares have increased by 35.0% and is now trading at $0.88. View the best growth stocks for 2023 here. Are investors shorting Context Therapeutics? Context Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 100,000 shares, a decrease of 15.6% from the April 30th total of 118,500 shares. Based on an average trading volume of 96,400 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.7% of the company's shares are sold short. View Context Therapeutics' Short Interest. When is Context Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our CNTX earnings forecast. When did Context Therapeutics IPO? (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share. What is Context Therapeutics' stock symbol? Context Therapeutics trades on the NASDAQ under the ticker symbol "CNTX." Who are Context Therapeutics' major shareholders? Context Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Investments LP (0.35%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Context Therapeutics' stock price today? One share of CNTX stock can currently be purchased for approximately $0.88. How much money does Context Therapeutics make? Context Therapeutics (NASDAQ:CNTX) has a market capitalization of $14.05 million. The company earns $-14,840,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. How can I contact Context Therapeutics? Context Therapeutics' mailing address is 3675 Market Street, Philadelphia, Pennsylvania 19104. The official website for the company is www.contexttherapeutics.com. The company can be reached via phone at 267-225-7416. This page (NASDAQ:CNTX) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.